TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35765748

Group type: EXPERIMENTAL
Intervention: 7-week attention training
Number of subjects: 82

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 82
Study: 33291185

Group type: EXPERIMENTAL
Intervention: Parent support program
Number of subjects: 128

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Baseline parental depression
Number of subjects: 128
Study: 35623315

Group type: EXPERIMENTAL
Intervention: MitoQ (20 mg/d)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 32917922

Group type: EXPERIMENTAL
Intervention: Leftward attentional shift (prismatic adaptation)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Rightward attentional shift (prismatic adaptation)
Number of subjects: 54
Study: 35988464

Group type: EXPERIMENTAL
Intervention: Intrapartum azithromycin (2g oral)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study: 34823296

Group type: EXPERIMENTAL
Intervention: Adjuvant radiation alone (282 patients)
Number of subjects: 848

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (281 patients)
Number of subjects: 848

Group type: EXPERIMENTAL
Intervention: Sequential chemoradiotherapy (285 patients)
Number of subjects: 848

Group type: EXPERIMENTAL
Intervention: Overall cohort (848 patients)
Number of subjects: 848
Study: 32540325

Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% eye drops
Number of subjects: 516

Group type: COMPARATOR
Intervention: Placebo eye drops
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Bilateral disease (yes vs. no)
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Higher baseline intraocular pressure (IOP)
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Disc hemorrhage at visit 1
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Smoking (current or previous)
Number of subjects: 516
Study: 34713987

Group type: EXPERIMENTAL
Intervention: PB2452 6 g i.v. bolus followed by 6 g infused over 4 h and then 6 g over 12 h
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 33142034

Group type: EXPERIMENTAL
Intervention: Keilland’s forceps delivery
Number of subjects: 971

Group type: COMPARATOR
Intervention: Primary full dilation caesarean section
Number of subjects: 971
Study: 36066009

Group type: EXPERIMENTAL
Intervention: Wild blueberry powder (n = 44)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo powder (n = 42)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Reference group (n = 45)
Number of subjects: 131
Study: 33586134

Group type: EXPERIMENTAL
Intervention: PSR model based on independent preoperative and postoperative predictors
Number of subjects: 1076

Group type: EXPERIMENTAL
Intervention: PSM model based on independent preoperative and postoperative predictors
Number of subjects: 1076
Study: 32722807

Group type: EXPERIMENTAL
Intervention: Higher γ' fibrinogen levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher total fibrinogen levels
Number of subjects: 0
Study: 33731525

Group type: EXPERIMENTAL
Intervention: ROTA + DES
Number of subjects: 332

Group type: COMPARATOR
Intervention: ROTA + POBA
Number of subjects: 332
Study: 33031472

Group type: EXPERIMENTAL
Intervention: Volar Locking Plate (VLP)
Number of subjects: 113

Group type: COMPARATOR
Intervention: External Fixation (EF)
Number of subjects: 113
Study: 35817072

Group type: EXPERIMENTAL
Intervention: Tixagevimab–cilgavimab
Number of subjects: 1417

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1417
Study: 33857436

Group type: EXPERIMENTAL
Intervention: ENDS with 36 mg/mL nicotine
Number of subjects: 520

Group type: COMPARATOR
Intervention: Cigarette substitute (non-ENDS)
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: ENDS with 0 mg/mL nicotine
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: ENDS with 8 mg/mL nicotine
Number of subjects: 520
Study: 32474156

Group type: EXPERIMENTAL
Intervention: Dupilumab 200 mg every 2 weeks
Number of subjects: 814

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks
Number of subjects: 814

Group type: EXPERIMENTAL
Intervention: Dupilumab treatment
Number of subjects: 814
Study: 36268807

Group type: EXPERIMENTAL
Intervention: Neurotec® herbal capsule (100 mg twice a day for three months)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 34837931

Group type: EXPERIMENTAL
Intervention: Mucosamin spray (3-4 times a day)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard medications (3 times a day)
Number of subjects: 80
Study: 35134800

Group type: EXPERIMENTAL
Intervention: S‐SNEDDS containing medium‐chain triglyceride (FS1)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: S‐SNEDDS containing long‐chain triglyceride (FS2)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Tablet of innovator product (FSt)
Number of subjects: 12
Study: 33546734

Group type: EXPERIMENTAL
Intervention: Continuation of RAAS inhibitors
Number of subjects: 40

Group type: COMPARATOR
Intervention: Temporary discontinuation of RAAS inhibitors
Number of subjects: 40
Study: 32101501

Group type: EXPERIMENTAL
Intervention: Polyetheretherketone (PEEK, Degos; G1)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Nano-ceramic composite (Lava Ultimate, 3M ESPE; G2)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Cast metal post (NiCr alloy, control; G3)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Fiberglass post (Whitepost, FGM, control; G4)
Number of subjects: 48
Study: 35696045

Group type: EXPERIMENTAL
Intervention: Nivolumab plus cabozantinib
Number of subjects: 320

Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 320
Study: 34580114

Group type: EXPERIMENTAL
Intervention: Veliparib plus modified FOLFIRI (veliparib 200 mg twice daily, days 1-7 with mFOLFIRI days 3-5)
Number of subjects: 123

Group type: COMPARATOR
Intervention: FOLFIRI (control)
Number of subjects: 123

Group type: COMPARATOR
Intervention: FOLFIRI in cancers with HR‐DDR defects
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Veliparib plus mFOLFIRI in cancers with HR‐DDR defects
Number of subjects: 123
Study: 36224739

Group type: EXPERIMENTAL
Intervention: 6% O₂ + 4% CO₂
Number of subjects: 26

Group type: COMPARATOR
Intervention: 6% O₂
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Combined hyperventilation and hypoxia training
Number of subjects: 26
Study: 34118783

Group type: EXPERIMENTAL
Intervention: IV metoclopramide + diphenhydramine
Number of subjects: 160
Study: 35450055

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine infusion (3 mg/kg/day for 5 days)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Intravenous saline infusion (50 ml/day for 5 days)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine infusion
Number of subjects: 72

Group type: COMPARATOR
Intervention: Intravenous saline infusion
Number of subjects: 72
Study: 32748404

Group type: EXPERIMENTAL
Intervention: Video invitation on a USB
Number of subjects: 1176

Group type: COMPARATOR
Intervention: Control group (invitation letter only)
Number of subjects: 1176

Group type: EXPERIMENTAL
Intervention: Participants who watched the video invitation
Number of subjects: 1176

Group type: EXPERIMENTAL
Intervention: Participants with lower income
Number of subjects: 1176
Study: 34049902

Group type: EXPERIMENTAL
Intervention: eTRIO (online caregiver communication education modules for oncology clinicians)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Control (Australian State Government Health website on caregivers)
Number of subjects: 270
Study: 32085793

Group type: EXPERIMENTAL
Intervention: Extensive mesenteric excision (EME)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Conventional ileocolic resection with limited mesenteric excision (LME)
Number of subjects: 116
Study: 33558198

Group type: EXPERIMENTAL
Intervention: Standard Pain Assessment Protocol (SPAP)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Routine care (comparison group)
Number of subjects: 101
Study: 32149929

Group type: EXPERIMENTAL
Intervention: Minimally invasive chevron osteotomy
Number of subjects: 39

Group type: COMPARATOR
Intervention: Open distal chevron osteotomy
Number of subjects: 39
Study: 35294297

Group type: EXPERIMENTAL
Intervention: Walking meditation (WM) group
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control (CON) group
Number of subjects: 33
Study: 32536425

Group type: EXPERIMENTAL
Intervention: TPVB with 20 mL 0.25% bupivacaine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no TPVB)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: TPVB
Number of subjects: 40
Study: 32505932

Group type: EXPERIMENTAL
Intervention: Case group (infants with hyperbilirubinemia)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (healthy infants)
Number of subjects: 100
Study: 36342252

Group type: EXPERIMENTAL
Intervention: 532-nm picosecond laser treatment (3 monthly treatments, 800 ps pulse duration, 4-6mm spot size, 0.1 to 0.6J/cm2 fluence)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 532-nm picosecond laser treatment
Number of subjects: 25
Study: 33756525

Group type: EXPERIMENTAL
Intervention: High-quality multi-ingredient nutritional supplement (SUPP) - 20 g whey protein, 2 g leucine, 2.5 g creatine monohydrate, 300 mg calcium citrate, 1000 IU vitamin D, ingested twice daily
Number of subjects: 26

Group type: COMPARATOR
Intervention: Isontrogenous isoenergetic placebo (PL) - 20 g collagen peptides, 1.4 g alanine, 0.6 g glycine, ingested twice daily
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: High-quality multi-ingredient nutritional supplement (SUPP)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Isontrogenous isoenergetic placebo (PL)
Number of subjects: 26
Study: 32247794

Group type: EXPERIMENTAL
Intervention: Subperiosteal drain (SPD)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Subdural drain (SDD)
Number of subjects: 133
Study: 34611051

Group type: EXPERIMENTAL
Intervention: Astaxanthin 6 mg/day for 4 weeks
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 33819166

Group type: EXPERIMENTAL
Intervention: Oxygen therapy with bilevel positive airway pressure (BiPAP) ventilation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Osteopathic manipulative respiratory and physical therapy techniques
Number of subjects: 60
Study: 32949031

Group type: EXPERIMENTAL
Intervention: Ceftolozane/tazobactam (C/T) 3-g dose (2 g ceftolozane and 1 g tazobactam) administered via a 1-hour infusion every 8 hours
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy participants
Number of subjects: 0
Study: 32244908

Group type: EXPERIMENTAL
Intervention: Cake and cookies intake
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Legumes intake
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: High-fat dairy and cheese intake
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Diet quality scores (derived Mediterranean and DASH diet)
Number of subjects: 136
Study: 33653009

Group type: EXPERIMENTAL
Intervention: High-NO3- (HN: 2 × 70 mL BJ/day)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Medium-NO3- (MN: 70 mL BJ/day)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Low-NO3- (LN: 70 mL BJ on alternate days)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo (PL: 70 mL of NO3--depleted BJ on alternate days)
Number of subjects: 62
Study: 32868354

Group type: EXPERIMENTAL
Intervention: Point-of-care (POC) VL testing (Cepheid Xpert HIV-1 Viral Load system) with same-day result and immediate ART adherence counselling
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard laboratory-based VL testing (Abbott m2000sp/m2000rt) with results available 1 month later and ART adherence counselling at that time
Number of subjects: 150
Study: 35907163

Group type: EXPERIMENTAL
Intervention: Indoor daylight photodynamic therapy (idl‐PDT)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Conventional photodynamic therapy (c‐PDT)
Number of subjects: 16
Study: 32229771

Group type: EXPERIMENTAL
Intervention: Resistance training with protein supplement (21 g whey protein per day, 90 kcal)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Resistance training with placebo (sucrose, 90 kcal)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both groups (RT + S and RT + P)
Number of subjects: 70
Study: 34560137

Group type: EXPERIMENTAL
Intervention: Intravenous belimumab 10 mg/kg
Number of subjects: 448

Group type: COMPARATOR
Intervention: Placebo with standard therapy (cyclophosphamide/azathioprine or mycophenolate mofetil)
Number of subjects: 448
Study: 32127350

Group type: EXPERIMENTAL
Intervention: Social support intervention
Number of subjects: 264

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 264
Study: 34069621

Group type: EXPERIMENTAL
Intervention: Group multicomponent cognitive‐behavioral therapy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 120
Study: 32624405

Group type: EXPERIMENTAL
Intervention: EBRT + BT
Number of subjects: 1650

Group type: COMPARATOR
Intervention: EBRT
Number of subjects: 1650
Study: 33316385

Group type: EXPERIMENTAL
Intervention: Omega-3 polyunsaturated fatty acids (OM3FA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Olive oil (as a placebo)
Number of subjects: 0
Study: 35938349

Group type: EXPERIMENTAL
Intervention: Test-1 (Trios 3/3Shape)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Test-2 (Virtuo Vivo/Straumann)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (Impregum/3M Espe)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Overall comparison of digital workflows
Number of subjects: 20
Study: 33983051

Group type: EXPERIMENTAL
Intervention: Zelesse cream (monotherapy for non-infectious VV)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Zelesse cream (adjuvant to antimicrobial therapy for infectious VV)
Number of subjects: 58
Study: 32629640

Group type: EXPERIMENTAL
Intervention: All-inside technique
Number of subjects: 70

Group type: COMPARATOR
Intervention: Inside-out technique
Number of subjects: 70
Study: 35353749

Group type: EXPERIMENTAL
Intervention: MCC‐PT (Managing Cancer Care: A Personal Guide)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Symptom management education (control)
Number of subjects: 71
Study: 33439606

Group type: EXPERIMENTAL
Intervention: COVID-19 impact on clinical responsibilities
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: COVID-19 impact on professional working time
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: Gender impact on job change due to COVID-19
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: Home responsibilities impact on job change
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: Early retirement plans due to COVID-19
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: Later retirement plans due to COVID-19
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: Burnout likelihood among women
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: Burnout likelihood among non-whites
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: Social isolation feelings
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: Job satisfaction association with retirement planning
Number of subjects: 561
Study: 32643385

Group type: EXPERIMENTAL
Intervention: Individual social communication intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peer intervention (adapted from the individual intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (individual intervention without peer involvement)
Number of subjects: 0
Study: 35784687

Group type: EXPERIMENTAL
Intervention: Withania somnifera (WS) root capsules, given twice a day for 12 weeks
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo (starch capsules), given twice a day for 12 weeks
Number of subjects: 150
Study: 32777986

Group type: EXPERIMENTAL
Intervention: 20m shuttle run test with music
Number of subjects: 386
Study: 33031171

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) for 4 weeks, performed on a cycle ergometer with 7.5% bodyweight resistance, consisting of 3×30-s maximal sprints with 2-min active recovery
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) for 4 weeks
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 41
Study: 36356616

Group type: COMPARATOR
Intervention: Regular wall‐slide exercises
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Theraband at the elbow
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Theraband at the wrist
Number of subjects: 20
Study: 32076716

Group type: EXPERIMENTAL
Intervention: Brincidofovir
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study: 35126900

Group type: EXPERIMENTAL
Intervention: Early enteral nutrition (EEN) support combined with chemotherapy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Chemotherapy only
Number of subjects: 80
Study: 33031833

Group type: EXPERIMENTAL
Intervention: Bezafibrate (400 mg once daily for 21 days)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Bezafibrate
Number of subjects: 74
Study: 34413152

Group type: EXPERIMENTAL
Intervention: Indwelling pleural catheters (IPC)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Therapeutic thoracentesis (TT)
Number of subjects: 68
Study: 34046892

Group type: EXPERIMENTAL
Intervention: Topical Epigallocatechin-3-gallate (EGCG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pimecrolimus
Number of subjects: 0
Study: 35445839

Group type: EXPERIMENTAL
Intervention: 600 mg of CBD
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 34590804

Group type: EXPERIMENTAL
Intervention: Neck and trunk stabilization exercises in addition to NDT-B approach
Number of subjects: 40

Group type: COMPARATOR
Intervention: NDT-B approach (Control)
Number of subjects: 40
Study: 36265571

Group type: EXPERIMENTAL
Intervention: Intact cord resuscitation (ICR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Early cord clamping-resuscitation (ECR)
Number of subjects: 0
Study: 34523740

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol treatment (800 ?g single dose)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 189
Study: 34470722

Group type: EXPERIMENTAL
Intervention: Pembrolizumab-pemetrexed maintenance plus SBRT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pembrolizumab-pemetrexed alone
Number of subjects: 0
Study: 32349927

Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT) plus docetaxel and estramustine (DE)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Androgen deprivation therapy (ADT)
Number of subjects: 78
Study: 35635482

Group type: EXPERIMENTAL
Intervention: Multi-Ingredient Supplement (MIS)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 56
Study: 33880554

Group type: EXPERIMENTAL
Intervention: Specialized nutritious food (SNF) treatment (1 of 4 types: 3 fortified-blended foods or a lipid-based nutrient supplement)
Number of subjects: 312
Study: 32937598

Group type: EXPERIMENTAL
Intervention: School-based exercise intervention (2 × 45 min/week)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (regular school physical education class only, 3 × 45 min/week)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: School-based exercise intervention
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 105
Study: 35584475

Group type: EXPERIMENTAL
Intervention: Wheelchair basketball (2 hours, twice a week for 12 months)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 48
Study: 34228837

Group type: EXPERIMENTAL
Intervention: Candesartan treatment in the DIRECT-Protect trials
Number of subjects: 1575
Study: 35930754

Group type: COMPARATOR
Intervention: Whole Breast Irradiation (WBI)
Number of subjects: 865

Group type: EXPERIMENTAL
Intervention: Partial Breast Irradiation (PBI)
Number of subjects: 865
Study: 34048061

Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (660 nm 200 mW CW applied at a distance of 1 cm to 4 points on the occlusal area, and 810 nm 200 mW CW applied at tissue surface at three points on the buccal and three points on the lingual gingiva for 15 seconds)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 0
Study: 33491400

Group type: EXPERIMENTAL
Intervention: HVGIC Equia Fil (ART method)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Filtek Z250 (Conventional method)
Number of subjects: 131
Study: 36402375

Group type: EXPERIMENTAL
Intervention: Methylene blue in sodium dodecyl sulfate
Number of subjects: 36

Group type: COMPARATOR
Intervention: Methylene blue in water
Number of subjects: 36
Study: 33514571

Group type: EXPERIMENTAL
Intervention: Leucine-rich protein supplement
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo with no supplemented protein
Number of subjects: 150
Study: 34486739

Group type: EXPERIMENTAL
Intervention: Motor performance
Number of subjects: 370

Group type: COMPARATOR
Intervention: Individual and environmental constraints and delayed learning of ADL
Number of subjects: 370
Study: 34198122

Group type: EXPERIMENTAL
Intervention: Culturally adapted manual-assisted problem-solving training (C-MAP) plus treatment as usual (TAU)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Culturally adapted manual-assisted problem-solving training (C-MAP)
Number of subjects: 221
Study: 32977969

Group type: EXPERIMENTAL
Intervention: Cardioplegia with diazoxide (500 μmol/L)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cardioplegia alone
Number of subjects: 12
Study: 34107724

Group type: EXPERIMENTAL
Intervention: Biopsychosocial holistic care models
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 140
Study: 32073660

Group type: EXPERIMENTAL
Intervention: Ubrogepant 50 mg
Number of subjects: 559

Group type: EXPERIMENTAL
Intervention: Ubrogepant 100 mg
Number of subjects: 559

Group type: EXPERIMENTAL
Intervention: Ubrogepant 25 mg
Number of subjects: 559

Group type: EXPERIMENTAL
Intervention: Ubrogepant 50 mg (pooled)
Number of subjects: 559